Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2016 Mar 30

PMID 27020103

Citations 28

Authors

Yanyan Jiang

Tom Verbiest

Aoife M Devery

Sivan M Bokobza

Anika M Weber

Katarzyna B Leszczynska

Ester M Hammond

Anderson J Ryan

Affiliations

Soon will be listed here.

Abstract

Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors potentiate radiation therapy in preclinical models of human non-small cell lung cancer (NSCLC) and other types of cancer. However, the mechanisms underlying radiosensitization in vivo are incompletely understood. Herein, we investigated the impact of hypoxia on radiosensitization by the PARP inhibitor olaparib in human NSCLC xenograft models.

Methods And Materials: NSCLC Calu-6 and Calu-3 cells were irradiated in the presence of olaparib or vehicle under normoxic (21% O2) or hypoxic (1% O2) conditions. In vitro radiosensitivity was assessed by clonogenic survival assay and γH2AX foci assay. Established Calu-6 and Calu-3 subcutaneous xenografts were treated with olaparib (50 mg/kg, daily for 3 days), radiation (10 Gy), or both. Tumors (n=3/group) were collected 24 or 72 hours after the first treatment. Immunohistochemistry was performed to assess hypoxia (carbonic anhydrase IX [CA9]), vessels (CD31), DNA double strand breaks (DSB) (γH2AX), and apoptosis (cleaved caspase 3 [CC3]). The remaining xenografts (n=6/group) were monitored for tumor growth.

Results: In vitro, olaparib showed a greater radiation-sensitizing effect in Calu-3 and Calu-6 cells in hypoxic conditions (1% O2). In vivo, Calu-3 tumors were well-oxygenated, whereas Calu-6 tumors had extensive regions of hypoxia associated with down-regulation of the homologous recombination protein RAD51. Olaparib treatment increased unrepaired DNA DSB (P<.001) and apoptosis (P<.001) in hypoxic cells of Calu-6 tumors following radiation, whereas it had no significant effect on radiation-induced DNA damage response in nonhypoxic cells of Calu-6 tumors or in the tumor cells of well-oxygenated Calu-3 tumors. Consequently, olaparib significantly increased radiation-induced growth inhibition in Calu-6 tumors (P<.001) but not in Calu-3 tumors.

Conclusions: Our data suggest that hypoxia potentiates the radiation-sensitizing effects of olaparib by contextual synthetic killing, and that tumor hypoxia may be a potential biomarker for selecting patients who may get the greatest benefit from the addition of olaparib to radiation therapy.

Citing Articles

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.

Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B Front Oncol. 2023; 13:1295579.

PMID: 38111536 PMC: 10726039. DOI: 10.3389/fonc.2023.1295579.

Cancer stem cells and their niche in cancer progression and therapy.

Liu Q, Guo Z, Li G, Zhang Y, Liu X, Li B Cancer Cell Int. 2023; 23(1):305.

PMID: 38041196 PMC: 10693166. DOI: 10.1186/s12935-023-03130-2.

PARP inhibitors combined with radiotherapy: are we ready?.

Sun C, Chu A, Song R, Liu S, Chai T, Wang X Front Pharmacol. 2023; 14:1234973.

PMID: 37954854 PMC: 10637512. DOI: 10.3389/fphar.2023.1234973.

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia.

Zhou R, Zhao D, Beeraka N, Wang X, Lu P, Song R Metabolites. 2022; 12(10).

PMID: 36295845 PMC: 9612299. DOI: 10.3390/metabo12100943.

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives.

Cesaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P Cancers (Basel). 2022; 14(12).

PMID: 35740495 PMC: 9221493. DOI: 10.3390/cancers14122829.

References

Bokobza S, Jiang Y, Weber A, Devery A, Ryan A . Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 88(4):947-54. DOI: 10.1016/j.ijrobp.2013.12.038. View

Jiang Y, Allen D, Kersemans V, Devery A, Bokobza S, Smart S . Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Lung Cancer. 2015; 90(2):191-8. PMC: 4641245. DOI: 10.1016/j.lungcan.2015.08.009. View

Zhan L, Qin Q, Lu J, Liu J, Zhu H, Yang X . Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells. Dis Esophagus. 2015; 29(3):215-23. DOI: 10.1111/dote.12299. View

Cohen-Jonathan E, Evans S, Koch C, Muschel R, McKenna W, Wu J . The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 2001; 61(5):2289-93. View

Loncaster J, Harris A, Davidson S, Logue J, Hunter R, WYCOFF C . Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001; 61(17):6394-9. View

Dehdashti F, Mintun M, Lewis J, Bradley J, Govindan R, Laforest R . In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003; 30(6):844-50. DOI: 10.1007/s00259-003-1130-4. View

Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B . PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys. 2004; 58(2):410-9. DOI: 10.1016/j.ijrobp.2003.09.053. View

Bindra R, Schaffer P, Meng A, Woo J, Maseide K, Roth M . Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004; 24(19):8504-18. PMC: 516750. DOI: 10.1128/MCB.24.19.8504-8518.2004. View

Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M . Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83(6):417-23. DOI: 10.1093/jnci/83.6.417. View

10.

Leith J, Quaranto L, Padfield G, Michelson S, Hercbergs A . Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int J Radiat Oncol Biol Phys. 1993; 25(2):283-7. DOI: 10.1016/0360-3016(93)90350-5. View

11.

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P . Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56(19):4509-15. View

12.

Rockwell S . Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res. 1997; 9(6-7):383-90. View

13.

Rogakou E, Pilch D, Orr A, Ivanova V, Bonner W . DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273(10):5858-68. DOI: 10.1074/jbc.273.10.5858. View

14.

Eschmann S, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G . Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005; 46(2):253-60. View

15.

Meng A, Jalali F, Cuddihy A, Chan N, Bindra R, Glazer P . Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol. 2005; 76(2):168-76. DOI: 10.1016/j.radonc.2005.06.025. View

16.

Noel G, Godon C, Fernet M, Giocanti N, Megnin-Chanet F, Favaudon V . Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther. 2006; 5(3):564-74. DOI: 10.1158/1535-7163.MCT-05-0418. View

17.

Schreiber V, Dantzer F, Ame J, de Murcia G . Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006; 7(7):517-28. DOI: 10.1038/nrm1963. View

18.

Tatum J, Kelloff G, Gillies R, Arbeit J, Brown J, Chao K . Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006; 82(10):699-757. DOI: 10.1080/09553000601002324. View

19.

Winter S, Buffa F, Silva P, Miller C, Valentine H, Turley H . Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007; 67(7):3441-9. DOI: 10.1158/0008-5472.CAN-06-3322. View

20.

Donawho C, Luo Y, Luo Y, Penning T, Bauch J, Bouska J . ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007; 13(9):2728-37. DOI: 10.1158/1078-0432.CCR-06-3039. View